Merck
Merck is a seed to Series E stage investment firm. It has made 53 investments. 36% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $83.2M (across 45 rounds with reported amounts).
Portfolio
53
Fund Size
—
Top Stage
Series A
Last 12 Mo
3
Team
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
61 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Terns Pharmaceuticals | Series C | $87M | May 2026 |
 FMC | Series C | — | Nov 2025 |
 Ferroelectric Memory | Series C | — | Nov 2025 |
 Actithera | Series A | $75.5M | Jul 2025 |
| PPAQ Therapeutics | Series B | $39M | May 2025 |
| VVariational AI | Seed | $5.5M | Feb 2025 |
| Ferroelectric Memory | Series C | — | Jan 2025 |
| AAnjuna Security | Unknown | $25M | Aug 2024 |
| GGRAIL, Inc. | Series B | $900M | Mar 2024 |
 beeOLED | Series A | — | Aug 2023 |
 Anavo Therapeutics | Seed | — | May 2023 |
 Calypso Biotech | Unknown | — | Jan 2023 |
 Solve Therapeutics | Series A | $126M | Dec 2022 |
 Photys | Series A | $75M | Sep 2022 |
 Orna Therapeutics | Unknown | $221M | Aug 2022 |
 Koneksa Health | Series C | $45M | Feb 2022 |
| KKoneksa | Series C | $4M | Feb 2022 |
| IInfectious Disease Connect | Unknown | $5.5M | Jan 2022 |
 Photys Therapeutics | Series A | $75M | Jan 2022 |
 Medisafe | Series C | $30M | Feb 2021 |
| AAdjuvant | Unknown | $300M | Feb 2021 |
 Adjuvant Capital | Unknown | $300M | Feb 2021 |
 LifeMine Therapeutics | Series B | $50M | Jan 2021 |
| Calypso Biotech | Series A | — | Jan 2021 |
| Calypso Biotech | Series A | — | Jan 2020 |
Page 1 of 3
Top Co-Investors
M Ventures14 shared
Novartis Venture Fund6 shared
MRL Ventures Fund6 shared
Surveyor Capital5 shared
MPM Capital5 shared
Celgene4 shared
Amgen Ventures4 shared
Pfizer Ventures4 shared
ARCH Venture Partners4 shared
Sunstone Life Science Ventures4 shared
McKesson Ventures4 shared
Tekla Capital Management3 shared
Eventide Asset Management3 shared
SV Health Investors3 shared
Samsara BioCapital3 shared
Alta Partners3 shared
Omega Funds3 shared
Bill & Melinda Gates Foundation3 shared
4BIO Capital3 shared
Last updated: 20 October 2026